AKY-2519: Phase 1b Trial Targets B7-H3 in Metastatic Prostate Cancer

AKY-2519, a miniprotein radioconjugate targeting B7-H3, has entered a Phase 1b clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC). The open-label study enrolls both PLUVICTO-naïve and PLUVICTO-experienced patients at multiple U.S. radioligand therapy centers, evaluating three dose levels in each cohort before expanding at selected doses. Preliminary safety and efficacy data from this […]

Newsletter 18/2026

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! This week I selected the studies I’ll be following during the ASCO 2026 annual meeting, which will take place at the end of the month. There are some very interesting things! But for now, let’s start with this week’s […]

GX-BP1: Targeting SOX2 to Prevent Resistance in mCRPC

GX-BP1, a bioPROTAC-based SOX2 degrader, selectively targets SOX2, an undruggable protein, for ubiquitin-proteasome elimination, overcoming limitations of prior inhibition strategies. In preclinical models, GX-BP1 monotherapy delivered approximately 70% tumor growth inhibition, while combinations with agents like carboplatin/paclitaxel achieved 87-96% inhibition and near-complete tumor suppression at optimal doses. Notably, GX-BP1 paired with osimertinib eradicated cancer stem […]

TLX597-Tx Shows Early Promise in a Phase 2 PSMA Trial for Prostate Cancer

TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) is emerging as a next-generation PSMA-targeted radioligand therapy designed to deliver radiation more precisely to prostate cancer cells while limiting exposure to healthy organs. New data from the OPTIMAL-PSMA trial suggest that the drug may achieve strong tumor uptake with relatively low dose to the salivary glands and kidneys, two of the main […]